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The present study demonstrates that blood samples can be used as a source of miRNA identiﬁcation asso-
ciated to Parkinson’s disease (PD). A set of six differentially expressed microRNAs were identiﬁed. They
form two groups according to their expression proﬁle in control, non-treated, early-onset and treatedvailable online 3 February 2011
eywords:
arkinson’s disease
icroRNA
eurodegenerative disease
Parkinson’s disease subjects. While miR-1, miR-22* and miR-29 expression levels allowed to distinguish
non-treated PD from healthy subjects, miR-16-2*, miR-26a2* and miR30a differentiated treated from
untreatedpatients. This study is innovative in contributing to thedevelopmentof effectivePDbiomarkers.
© 2011 Elsevier B.V. Open access under the Elsevier OA license.T-qPCR
olecular marker
. Introduction
Parkinson’s disease (PD) is a neurodegenerative disease charac-
erized by resting tremor, rigidity, bradykinesia and loss of postural
eﬂexes. Subjects with PD also can show a variety of non-motor
ymptoms including cognitive impairment, depression and sleep
isorders (Poewe, 2008; Chaudhuri and Odin, 2010).
The molecular mechanism of neurodegeneration in PD is
ostly unknown. Pathologically, PD is characterized by the loss of
opaminergic nigral neurons, accompanied by gliosis and the pres-
nce of eosinophilic intracytoplasmic inclusions known as Lewy
odies in the remaining substantia nigra pars compacta neurons.
lpha-synuclein is the principal component of ﬁlamentous of Lewy
odies, the deﬁning pathological hallmark of PD (Spillantini et al.,
997). It is now recognized that PD is also associated with exten-
ive nondopaminergic pathology (Braak et al., 2003). The etiology
f PD is a complex interaction among genes, environment andbrain
ging. Although in a minority of cases it is due to well-deﬁned
enetic causes, a combination of genetic and environmental fac-
ors are believed to account for the vast majority of cases. This
ncludes interactions between several genes, modifying effects by
usceptibility alleles, the inﬂuenceof environmental agentsongene
xpression and their direct impact on the developing and aging
rain (Klein and Schlossmacher, 2007).
∗ Corresponding author at: Center of Biotechnology, Federal University of Rio
rande do Sul, Av Bento Goncalves 9500, Predio 43431, sala 213 CxP. 15005, 91501-
70 Porto Alegre, RS, Brazil. Tel.: +55 51 33087766.
E-mail address: rogerio.margis@ufrgs.br (R. Margis).
168-1656 © 2011 Elsevier B.V. Open access under the Elsevier OA license.
oi:10.1016/j.jbiotec.2011.01.023The use of biomarkers remains investigational in PD. A
biomarker is a characteristic that is objectively measured as an
indicator of normal or pathogenic biologic processes, or a phar-
macological response to a treatment. Biomarkers can help to
determine disease pathophysiology and a drug’s mechanism of
action (Rascol, 2009). The identiﬁcation of potential biomarkers
in PD would be of remarkable value. Currently, there is no reli-
able biomarker for PD, except in a small minority of patients with
a monogenetic form of the disorder, in whom at least the under-
lying disease trait can be unequivocally determined by mutational
analysis. However, even in these patients, the relationship between
the biomarker (amutation detectionmethod) and disease develop-
ment is complex because of the often reduced and age-dependent
penetrance and variable expressivity (Gasser, 2009).
The genetic dissection of common diseases such as PD is a cur-
rent challenge of medical genomics. Several diseases have genetic
components that are not easily detected, in part because loci
involved in these conditionsmayhavea small size effects, and these
locimay interact among them. Thismay not be the case formicroR-
NAs,whichcan regulatea large setof genes fromdifferentpathways
at the transcriptional and translational levels. Indeed, microRNAs
have been used asmolecularmarkers in a series of diseases, includ-
ing cancer, neurodegenerative disorders and others (Bartels and
Tsongalis, 2009; Nelson et al., 2008; Pauley et al., 2009). Recently,
it has been proposed that microRNAs (miRNAs) can play a role in
PD (Barbato et al., 2009; Eacker et al., 2009; Kim et al., 2007).
MicroRNAs are evolutionarily conserved, small, approximately
22 nucleotides, non-coding RNAs. Most miRNAs are thought to
post-transcriptionally inhibit protein coding genes by affecting
their translation and/or mRNA stability (Bartel, 2004; Filipowicz
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t al., 2008). The miRNAs bind multiple target RNA species and
re associated with many biological functions (Ambros, 2004) like
euronal gene expression (Wu and Xie, 2006) and pathological
rocesses like the development of cancer (Meltzer, 2005), neurode-
enerative disorders (Saugstad, 2010; Weinberg and Wood, 2009)
nd schizophrenia (Perkins et al., 2007).
The present study was designed to evaluate the expression
f miRNAs in de novo PD (non-treated patients) and the effect
f levodopa treatment on miRNA expression. Patients with early
anifestation of the disease present a high incidence of affected
rst-degree relatives, indicating that genetic factors play a role in
athogenesis. Thereforewe also evaluated if therewere differences
n miRNA between early-onset and late-onset PD.
. Methods
.1. Subjects and procedures
This study was approved by the local ethics committee and all
ubjects provided informed consent before entering into the study.
ifteen PD patients attending an outpatient Movement Disorders
linic of a university hospital in Southern Brazil were included in
he study. EightwereuntreatedPDpatients (NTgroup)with amean
ge of 66 years (sd 6.7) and seven were early-onset Parkinson’s dis-
ase (EOPD) subjects with a mean age of 45 years (sd 8.7). Disease
uration was 3.0 (sd 2.6) and 7.2 years (sd 6.6) in the NT and EOPD
roups, respectively. Each group was constituted by 50% males.
All patients fulﬁlled the clinical criteria for PD (the United King-
om Parkinson’s Disease Society Brain Bank clinical diagnostic
riteria) (Hughes et al., 1992). Exclusion criteria were as follows:
1) presence of other neurological disease; (2) presence of psy-
hiatric disorder according to a structured clinical interview; (3)
ini-Mental StateExamination (MMSE) (Folsteinet al., 1975) lower
han 24 (Almeida, 1998). The semi-structured interview was used
o collect information on demographic variables, disease history
nd drug record.
The control group (CNT group) was constituted by eight no-PD
olunteerswith ameanageof 67 years (sd 8.0). These subjectswere
elected among outpatient clinics and among PD spouses. Control
roup exclusion criteria were the same as described above.
PD symptoms were evaluated using the Uniﬁed Parkinson’s
isease Rating Scale (UPDRS) (Fahn and Elton, 1987) and the
oehn and Yahr modiﬁed version (HY) (Hoehn and Yahr, 1967).
ost of the NT subjects (62.5%) showed unilateral motor impair-
ent only, corresponding to HY-1stage; while 37.5% of the NT
atients had presented bilateral or midline involvement without
mpairment of balance (HY-2 stage). Distribution of the Hoehn-
ahr Staging among EOPD subjects was as following: HY 1(42.8%),
Y-2 (28.6%) and HY-3; corresponding to bilateral disease with
ild to moderate disability and postural reﬂexes impairment
28.6%). Levodopa/carbidopa treatment resulted in motor symp-
oms improvement evaluated by UPDRS.
Sleep and depressive symptoms were assessed by Pittsburgh
leep Quality Index (PSQI) (Buysse et al., 1989) and Beck Depres-
ion Inventory (BDI) (Beck et al., 1961), respectively. As expected,
onsidering that sleep disturbances are a frequent problem in PD
atients (Tandberg et al., 1998),NTgroup showedworse sleepqual-
ty evaluated by PSQI score than control group (mean± sd: 9.4±4.8
nd 4.4±2.5; respectively). PSQI scorewas 5.7±3.9 in EOPDgroup.
ubjects showed mean BDI scores that were below the cutoff pro-
osed for depression screening (Schrag et al., 2007). No signiﬁcant
ifferences in MMSE score were found between groups.
Blood sampleswere taken fromall subjects interviewed:denovo
D (NT group), early-onset PD (EOPD group), control subjects (CNT
roup) and from four randomly selected previously untreated PDnology 152 (2011) 96–101 97
patients after 97 (±39) days of the levodopa/carbidopa treatment
(T group).
2.2. Quantitative real time PCR
Peripheral blood samples were obtained between 5 and 8 PM
and immediately mixed with a ﬁve-fold volume of Trizol (Invit-
rogen) for total RNA extraction. Mature microRNA expression was
evaluated by quantitative real time PCR (RT-qPCR) of microRNAs
by stem-loop RT-PCR, as described by Chen et al. (2005).
Mature miRNA cDNA was synthesized according to the fol-
lowing: 100ng of total RNA(1:20); 4l of stem loop primer mix
(Supplementary Table 1) (0.4M each); 0.4l of M-MLV reverse
transcriptase (Promega) 200U/l; 4l M-MLV reverse transcrip-
tase 5X reaction buffer (Promega) and 2l of 5mM dNTP in a ﬁnal
volume of 20l. The synthesis of the cDNA was completed after a
series of three incubations: 16 ◦C for 30min, 42 ◦C for 30min and
85 ◦C for 5min.
The RT-qPCR mix: 10l of cDNA (1:30); 0.4l of speciﬁc
microRNAs forward primer (Supplementary Table 1) (20M)
and universal reverse primer (Supplementary Table 1) (10M)
primers; 0.4l of 5mM dNTPs; 2l of 10X PCR buffer; 1.2l of
50mM MgCl2; 2l of 1X SYBR Green® (Molecular probes); 0.05l
of Platinum Taq DNA polymerase (Invitrogen) to a ﬁnal volume of
20l. SYBR-Green® was used to detect ampliﬁcation, estimate CT
values and todetermine speciﬁcity aftermelting curveanalysis. The
PCR cycling conditions were standardized to: 94 ◦C for 5min fol-
lowed by 40 cycles at 95 ◦C for 15 s, 60 ◦C for 10 s and 72 ◦C for 15 s.
After the main ampliﬁcation, sample ﬂuorescence were measured
at temperatures from 55 to 99 ◦C with an increasing ramp of 0.1◦ C
in order to obtain the denaturing curve of the ampliﬁed products
and assure their homogeneity after peak detection and Tm esti-
mation using data obtained from an Applied Biosystems StepOne
system.
As an initial step of this study, a PCR array was performed with
microRNAs previously reported as potentially associated with both
sleep deprivation (Davis et al., 2007) and neurodegenerative disor-
ders (Barbato et al., 2009; Eacker et al., 2009; Kimet al., 2007;Wang
et al., 2008). The complete list of the 85 microRNAs used in the
PCR array are indicated in Supplementary data Table 2. A set of six
microRNAswithmore informative expressionpatterns amongeach
experimental group was chosen. The group was composed of miR-
1, miR-22*, miR-29a, miR-16-2*, miR-26a2* and miR-30a, which
were selected out of 85 microRNAs present in the initial screening
due their differential expression patterns.
2.3. Data analysis
The six selected microRNAs presented an efﬁciency of ampli-
ﬁcation in the 0.94–0.98 range among the different cDNA-derived
blood samples, as calculated by internal sample exponential ampli-
ﬁcation analysis (Ramakers et al., 2003). The relative expression
wasobtainedusing the2−Ct methodwhere theCrossing threshold
(Ct) values of the target samples are subtracted from the average Ct
values of the standard or control samples. The use of 2−Ct is ade-
quate, as the amount of RNA among the different blood samples to
produce the cDNAs did not differ signiﬁcantly and produced sim-
ilar Ct values among samples for 20 different microRNAs used in
the initial screening (data not shown).
Statistical analysis of the relative expression values obtained
for each microRNA between pairs of experimental groups were
performed by Student’s t-test implemented in SPSS Statistics 17
software. In order to compare the expression levels among the
four experimental groups, theWaller–Duncan and TukeyHSD tests
were performed with SPSS 17, with identical group discrimination
and similar probability values.
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Fig. 1. Relative expressions of miR-1, miR-22* and miR-29a among the patient
groups. Mean (± standard deviation) miRNA relative expression in blood of the con-
trol (CNT), de novo PD (NT), treated PD (T) and early-onset PD (EOPD). Mir1: lower
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Fig. 2. Pairwise analysis of the set of sixmiRNAs:miR-1,miR-22*,miR-29a,miR-16-
2*, miR-26a2* and miR-30a. Data represent mean (± standard deviation) of miRNA
relative expression. (A) De novo PD group (NT) showed lower miR1, miR-22* and
miR-29a relative expression than the control group (CNT); NT and CNT presented no
statistical difference in miR16-2, miR-26a2* and miR30a; Student’s t test, asterisks
indicate p<0.05, triangle indicates p=0.007. (B) Higher miR16-2* and miR26a2*
relative expression occurred in early–onset Parkinson’s disease (EOPD) than theCNTxpression in NT than CNT and EOPD; miR-22*: a trend to lower expression in NT
han CNT; miR-29a: lower expression in NT (statistically signiﬁcant) and T (trend)
han the CNT group. Waller–Duncan and Tukey HSD tests; double asterisks indicate
<0.05, single asterisks indicates p=0.07.
The target microRNAs that have the potential binding sites for
ndividual microRNAs were identiﬁed by searching them on public
atabases endowed with prediction algorithms present in miRBase
Mendes et al., 2009).
. Results and discussion
A set of three miRNAs, miR-1, miR-22* and miR-29a, showed
educed proﬁles of relative expression in the de novo PD (NT) and
reated groups (T) when compared to control subjects (CNT) and
he early-onset PD group (EOPD) (Fig. 1). NT group had signif-
cantly lower miR-1 expression than the CNT and EOPD groups
p=0.031andp=0.015, respectively). In addition,miR-1expression
as not statistically different between the T group, which was con-
tituted by NT patients after levodopa treatment and CNT subjects.
t suggests that levodopa treatment can play a role in restor-
ng normal miR-1 relative expression levels. De novo PD patients
lso showed low relative miR-22* expression. In comparison with
he CNT group, NT subjects showed a trend toward low miR-22*
xpression (p=0.067). Considering miR-29a, the NT group showed
ower miR-29a expression than the CNT group, and levodopa treat-
entdidnot signiﬁcantly change this expression. Interestingly, low
iR-29a expression was maintained after treatment; the T group
howed a trend to lower expression than the CNT group.
A second set of three miRNAs, miR-16-2*, miR-26a2* and
iR-30a, presented no statistical differences in their relative
xpressions between the CNT and NT groups (Fig. 2A). These same
iRNAs showed a 50% increase in their relative expression in
he groups constituted by PD patients taking dopaminergic drugs,
OPD compared to CNT group (Fig. 2B), while only miR-16-2* and
iR-26a2* were increased in treated individuals (T) compared to
he NT group (Fig. 2C).
Examples of differential miRNA expression have been shown
n patients and animal models of neurodegenerative disorders
Roshan et al., 2009). In a mouse model of PD, miR-133b was
ound to be downregulated (Kim et al., 2007), and analyses on post-
ortem tissue showed a decreased expression of miR-133b in the
idbrain of patients with PD. However, in our study using blood
amples, this miRNA did not show altered expression.
The miRNAs can act at many stages to trigger the produc-
ion or degradation of toxic proteins, and changes in these steps
ay have a role in the neurodegenerative process (Eacker et al.,
009). Alpha-synuclein accumulation can interfere with -tubulin
olubility and distribution, leading to neuronal dysfunction. Alpha-group; Student’s t test, double asterisks indicate p<0.01, triangle indicates p=0.07.
(C) Treated group (T) showed higher miR-16-2* and miR-26a2* than the NT group;
Student’s t test, asterisks indicate p<0.05.
synuclein overexpression impairs microtubule – dependent trafﬁc,
(Lee et al., 2006) and in its aggregated forms, plays a critical
role in the pathogenesis of PD. Tubulin polymerization-promoting
protein (TPPP/p25) interacts with the tubulin/microtubule system
in vitro and in vivo, and is enriched in human pathological brain
inclusions. The primary intracellular target of TPPP/p25 is tubu-
lin/microtubules (Hlavanda et al., 2002) and abnormal TPPP/p25
accumulation has been associated with alpha-synuclein aggre-
gates. It has been proposed that upregulated TPPP/p25 could be
a speciﬁc marker for pathological conditions associated with abun-
dant aggregationof alpha-synuclein, suchasPD (Kovács et al., 2004;
Kovács et al., 2007). It should be noted that TPPP/p25 is a target of
miR-1,which, in the present study, showed lower expression levels
in de novo PD when compared with healthy subjects.
iotechnology 152 (2011) 96–101 99
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Fig. 3. GroupedmiRNArelative expression analysis. (A)Altogether,miR-16-2*,miR-
26a2* and miR-30a relative expression analysis showed a signiﬁcant difference
between treated (T and EOPD) and untreated groups (B) assemblage of miR-1, miR-R. Margis et al. / Journal of B
In addition to TPPP/p25, clathrin heavy chain (CHC) is also a tar-
et of miR-1. Studies have indicated that clathrin may be involved
n mediating microglial endocytosis of aggregated alpha-synuclein
nd associated with microglial activation (Liu et al., 2007). Knock-
own of CHC by small interfering RNAs inhibited both constitutive
nd protein kinase C-mediated internalization of the dopamine
ransporter (DAT) (Sorkina et al., 2005). Peripheral blood lym-
hocytes also express many neurotransmitters and neuropeptide
eceptors. Previous studies have shown that blood samples fromPD
atientspresent increasedexpressionofCLTB (Scherzer et al., 2007)
nd dopamine receptors on lymphocytes (Barbanti et al., 1999).
Considering the current study data, it should be noted that
opamine transport regulation in PD patients is related to miR-
and mir-30a. The former is associated with CHC properties, as
escribed above, and miR-30a has SLC6A3 (solute carrier family 6
neurotransmitter transporter – dopamine) as a potential target.
he plasma membrane dopamine transporter (DAT) present at the
ell surface is regulated by the rate of DAT internalization to endo-
omes and DAT recycling back to the plasma membrane. DAT is
xpressed in presynaptic terminals of substantia nigra dopaminer-
ic neurons, where it mediates the re-uptake of synaptic-released
opamine.Alpha-synuclein acts in themodulationofDAT functions
y regulating synaptic tone of dopamine (Sidhu et al., 2004).
Moreover, miR-30a may also target ﬁbroblast growth factor
FGF20), which is targeted by miR-16-2*. In this study, both miR-
0a and miR-16-2* showed the highest expression in PD subjects
fter levodopa treatment. A previous study identiﬁed a pointmuta-
ion in PD patients in the 3′UTR of FGF20 that disrupts the miR-433
inding site (Wang et al., 2008). Expression of miR-433 was also
nalyzedbutdidnot showdifferences amongdifferent groups (data
ot shown).
Like miR-16-2*, our data demonstrated that PD subjects after
evodopa treatment have higher miR-26a2* expression than the de
ovo PD group. miR-26a2* has a tyrosinase precursor gene as one
f its potential targets. Another potential target of miR-26a2* is the
lutamate receptor 1 precursor (GRIA1), as with miR-30a. Studies
ave demonstrated that glutamatergic regulation can take place in
D symptoms and treatment (Calón et al., 2003).
The assembly of miR-16-2*, miR-26a2* and miR30a presented
igher expression in treated PD (Fig. 3A). The treatment effects
ere evaluated in two groups: T and EOPD. These miRNAs showed
he highest expression in the EOPD group. It should be noted that
he EOPD group consisted of patients that were submitted to more
hanoneantiparkinsoniandrug, and theyhada longerdiseasedura-
ion than the T group. When miR-16-2*, miR-26a2* and miR-30a
ereanalyzed together,we identiﬁed that theywereexpressed sig-
iﬁcantly higher in both treated groups (EOPD and T groups) than
n the CNT and NT groups. A statistical difference was not observed
hen this analysiswas performed between the EOPD and T groups,
einforcing the potential role of the antiparkinsonian drug in these
iRNAs expressions.
The miR-1, miR-22* and miR-29a expression levels evaluated
ogether showed that the EOPD group had higher expression lev-
ls than the NT and T groups (Fig. 3B). It should be noted that
istinct mechanisms can underlie these results. There are some
dditional features implicated in these data, including that the
OPDandTgroups receiveddistinct antiparkinsoniandrugs,whose
echanism of action, as well the treatment duration, could exert
nterference in miRNA expression. Considering the EOPD and NT
roups, it should be noted that some group characteristics like dis-
ase duration and EOPD pathophysiology may contribute to these
esults.
Relative expression of miR-1, miR-22* and miR-29a analyzed
ogether did not show a signiﬁcant distinction between the NT
nd T groups. Each of these miRNAs (miR-1, miR-22* and miR-29a)
howed lower expressions in the NT group compared to the CNT22* and miR-29a expression showed lower expression in de novo PD (NT) than the
control (CNT) and early–onset Parkinson’s disease (EOPD) groups. Waller–Duncan
and Tukey HSD tests; different letters indicate statistically signiﬁcant differences
between groups, p<0.05.
group, indicating a possible regulatory mechanism among their
targets. Some miR-1 targets have been mentioned previously in
this text. Concerning miR-22*, it is appropriate to remark on two
of its potential targets: tumor suppressor p53-binding protein 2
(TP53BP2) and GRIA. As cited above, GRIA is also targeted by miR-
26a2* and miR-30a.
According to the present data, miR-29a was the only miRNA
evaluated where the decreased expression observed in the NT
group was maintained after levodopa treatment (Fig. 1). These
results allow us to suggest that (i) mir-29a is associated with PD, as
demonstrated by the relative expression difference between the
NT and control groups, and that (ii) the lower miR-29a expres-
sion in PD should not be directly related to the occurrence of
motor symptom changes because the decreased miR-29a expres-
sion was maintained despite motor symptom improvement. This
maintained low expression pattern evokes special interest in terms
of miR-29a having a role in PD.
Cell division cycle 42 (CDC42), which is related with septin,
is targeted by miR-29a. Recently, postmortem substantia nigra of
a PD study described the presence of increased levels of septin4
and the parallel increase of septin4 and alpha-synuclein in PD
(Shehadeh et al., 2008). Curiously, the expression of miR-29a has
also a decreased expression level in Alzheimer’s disease, in associ-
ation with increased BACE1/beta-secretase expression and neuron
navigator (Hébert et al., 2008; Shioya et al., 2010).
Considering the neurodegenerative process and cell damage
occurrence in PD, some miRNAs evaluated in the present study
also have trophic factors as their targets. This can be understood,
in one way, as a kind of compensatory mechanism target by some
miRNAs. Conversely, the reduction of these trophic factors by dis-
tinct features, suchasaging,mayexacerbate theneurodegenerative
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rocess. Itmust be considered that brain-derived neurotrophic fac-
or’s (BDNF) ability to protect neuronal activity can be affected by
ging (Sohrabji and Lewis, 2006). Animal models have shown that
ncreased BDNF expression following striatal damage can be ben-
ﬁcial to dopaminergic neurons; however, these changes in BDNF
xpressionmaybe lostwith age (Batchelor et al., 1999; Collier et al.,
005).
BDNF has been identiﬁed as a potential target of miR-1. It is
resent in neurons, glia and peripheral immune cells. BDNF pro-
otes the survival of dopaminergic neurons and protects them
rom toxin-induced damage in vitro (Murer et al., 2001). BDNF lev-
ls are increased in PD cerebral spinal ﬂuid when compared with
ormal subjects (Salehi and Mashayeki, 2009). This BDNF elevation
nCSFmaybe causedby an increasedgenerationof glial cells result-
ng from brain damage (Knott et al., 2002). Production of BDNF by
lial cells in PD patients may represent an active response to neu-
odegeneration (Salehi andMashayeki, 2009). The reduced levels of
iR-1, detected in non-treated PD subjects, are in agreement with
n increase in BDNF mRNAs and the previously described BDNF
rotein levels.
Insulin-like-growth factor-1 (IGF-1) is also linked to the preser-
ation and homeostasis of the nervous system.MiR-1,miR-29a and
iR-30 all target IGF-1. Serum and brain IGF-1 levels change in
everal human neurodegenerative diseases (Busiguina et al., 2000).
ecently, a study found that blood IGF-1 levels, although statisti-
ally non-signiﬁcant, were mildly elevated in treated PD patients
n comparison with controls (Tuncel et al., 2009).
We have shown miRNA expression levels from peripheral blood
ources and discussed some potential miRNA targets that could be
elated to PD pathophysiology. Some limitations should be kept
n mind considering the results of this study, like the small sam-
le size and properties of miRNA. A single miRNA can target many
ranscripts and a single transcript can be targeted by many miR-
As, transcripts can present differences in tissue distribution. We
re concerned that the present results were obtained from blood,
nd that these miRNAs may show different expression patterns in
rain tissue. Moreover, these differences in miRNA expression may
ven occur among distinct brain areas (Davis et al., 2007; Kim et al.,
007). TheextentofmiRNAexpressionpattern correlationbetween
eripheral blood and different brain structures should be evaluated
n future research.
. Conclusion
MiR-1, miR-22* and miR-29a showed low expressions in
D blood samples. Altogether, this miRNAs expression analysis
howed a signiﬁcant distinction between the NT and control group.
iR-16-2*, miR-26a2* and miR30a expression levels allowed us
o distinguish treated from untreated patients. Despite the cellu-
ar functions of many human miRNAs remaining unknown and the
omplexity of Parkinson’s disease, we assume that further miRNA
tudies will contribute to PD biomarker development. In addition,
eripheral blood as a source of this information could facilitate
iRNA studies in humans, as well their future clinical applicability.
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